Cure

TSC Alliance® to Host 23rd Annual Comedy for a Cure® on April 14 in Los Angeles

Retrieved on: 
Friday, March 15, 2024
TSC, Jim, Learning, Parks and Recreation, Disease, Patient, The King of Queens, Neoplasm, DSM-IV codes, Research, Courage, Vibiana, The Tonight Show, Ovation, Movement disorder, Jazz, Jazz Pharmaceuticals, Comedy, Cure, Pharmaceutical industry

LOS ANGELES, March 15, 2024 /PRNewswire/ -- Today, the TSC Alliance ® announced its 23nd Annual Comedy for a Cure ® will be held Sunday, April 14, at the historic Vibiana in Los Angeles.

Key Points: 
  • LOS ANGELES, March 15, 2024 /PRNewswire/ -- Today, the TSC Alliance ® announced its 23nd Annual Comedy for a Cure ® will be held Sunday, April 14, at the historic Vibiana in Los Angeles.
  • "Every year, Comedy for Cure helps our organization raise significant funds to further TSC research, offer expanded support programs and increase awareness about the disease," said Kari Luther Rosbeck, TSC Alliance President & CEO.
  • "Over the years, this signature event has raised almost $6 million cumulatively to help improve the lives of everyone affected by TSC."
  • Comedy for a Cure also offers the opportunity to pay tribute to those who have made significant impacts in the right against TSC.

Aegis Living Appoints Renowned Pulmonary and Sleep Expert Dr. Raj Dasgupta as Chief Medical Officer

Retrieved on: 
Tuesday, March 12, 2024
Internal medicine, Health, Longevity, Thomas Jefferson University, Sleep hygiene, Associate, Philosophy, Aegis, Diabetes, Television, Medicine, FACP, Research, Sleep, CNN, Columbia University, University, USC, Quality of life, Jefferson Abington Hospital, News, Michigan State University, Cognitive behavioral therapy, Mount Sinai West, FCCP, Nursing care plan, CMO, Cure, ABC News, Dementia

BELLEVUE, Wash., March 12, 2024 /PRNewswire/ -- Aegis Living, a national leader in senior assisted living and memory care, has appointed Raj "Dr. Raj" Dasgupta MD, FACP, FCCP, FAASM, as Chief Medical Officer (CMO). Dr. Raj's appointment strengthens Aegis' healthcare expertise to further integrate wellness and longevity into the care of its residents, families and team members.

Key Points: 
  • BELLEVUE, Wash., March 12, 2024 /PRNewswire/ -- Aegis Living , a national leader in senior assisted living and memory care, has appointed Raj "Dr. Raj" Dasgupta MD, FACP, FCCP, FAASM, as Chief Medical Officer (CMO).
  • While one's lifespan defines how long they will live, healthspan is the quality of life that Aegis Living aims to impact.
  • While the primary beneficiaries will be Aegis Living residents and families, Aegis also aims to support and influence team members.
  • "I am honored to join the leadership team at Aegis Living to advance the level of care and wellness not yet experienced in senior living," said Dr. Raj.

Dr. Samuel Lin Continues Partnership With Haute Beauty Network

Retrieved on: 
Friday, February 2, 2024
Partnership, Northwestern University, Certification, AAPS, ABMS, Plastic surgery, Knowledge, Science, Bachelor, Feinberg School of Medicine, Rhinoplasty, Division, Medical specialty, Internet celebrity, Expert, Plastic and Reconstructive Surgery, Biomedicine, Mentorship, Literature, MD Anderson Cancer Center, Elective surgery, Honors colleges and programs, Medical education, Harvard University, Harvard Medical School, Physician, Northwestern Memorial Hospital, Breast surgery, Biomedical engineering, Cure, Pearl, Editorial, Associate, University, Student, Editor-in-chief, Dentistry

NEW YORK, Feb. 2, 2024 /PRNewswire-PRWeb/ -- Dr. Samuel Lin is a double board certified Plastic Surgeon and Associate Professor of Surgery at Harvard Medical School who practices in Boston, Massachusetts. Dr. Lin received his Bachelor's degree in Biomedical Engineering at Northwestern University and was enrolled in the Honors Program for Medical Education at Northwestern University, Feinberg School of Medicine, Chicago, Illinois. He then completed a five-year-residency in Otolaryngology-Head and Neck Surgery followed by a three-year-residency in Plastic and Reconstructive Surgery at Northwestern Memorial Hospital. This was followed by a one-year fellowship appointment in Microvascular Reconstructive Surgery at the world-renowned University of Texas M.D. Anderson Cancer Center in Houston, Texas. Throughout the course of his training, Dr. Lin gained state-of-the-art skills in a multitude of reconstructive and cosmetic procedures with his background in Head and Neck Surgery providing him with additional expertise in Plastic and Reconstructive Surgery. He has also been named a Top Influencer in #PlasticSurgery.

Key Points: 
  • Nose Expert from Boston, Dr. Samuel Lin, continues his partnership with Haute Beauty Network, now in his sixth year.
  • NEW YORK, Feb. 2, 2024 /PRNewswire-PRWeb/ -- Dr. Samuel Lin is a double board certified Plastic Surgeon and Associate Professor of Surgery at Harvard Medical School who practices in Boston, Massachusetts.
  • Dr. Lin is board certified by both the American Board of Plastic Surgery and the American Board of Otolaryngology-Head and Neck Surgery.
  • Dr. Lin, his team, and his collaborators regularly publish scientific papers in the literature to further knowledge about plastic surgery and other topics.

New Arkansas Organization Will Support Healthy Families by Listening to Parents, Advocating for Better Maternal Health Care

Retrieved on: 
Wednesday, January 17, 2024
Mortality, AIM, Death, Woman, Medicine, Statistics, Legislation, Research, Hospital, Heifer International, Medicaid, Mother, PTSD, Life, Maternal health, Multimedia, Insurance, NICU, University, Mental health, Anxiety, Nursing, Pregnancy, Cure, Disease, Mental, Prenatal care, Workforce, Parent, Infant, Birth control

LITTLE ROCK, Ark. , Jan. 17, 2024 /PRNewswire/ -- A new maternal health non-profit organization has launched a digital platform for Arkansas parents to share their personal experiences before, during and after pregnancy. Maternal healthcare includes prenatal care, safe delivery and postpartum support like mental healthcare.

Key Points: 
  • Arkansans for Improving Maternal Health promotes healthy moms, which leads to healthier families and stronger communities
    LITTLE ROCK, Ark.
  • , Jan. 17, 2024 /PRNewswire/ -- A new maternal health non-profit organization has launched a digital platform for Arkansas parents to share their personal experiences before, during and after pregnancy.
  • Driven by research that shows Arkansas has the highest maternal mortality rate in the nation and that healthy moms lead to healthier families and stronger communities, Arkansans for Improving Maternal Health (AIM) is gathering stories from families impacted by poor maternal health outcomes.
  • Research by the Arkansas Maternal Mortality Review Committee shows that 92% of maternal deaths in Arkansas could be prevented by enhancing the quality of maternal health care.

Music can ease the January blues – but the types of songs that work depend on your age and mindset

Retrieved on: 
Tuesday, January 16, 2024
Noise, Patient, Trauma, Research, Weight loss, Sadness, Happiness, Mental health, Anxiety, Cure, Emotion, Exercise, Sensation, Pleasure, Catharsis, Music

So what type of music should you turn to in order to boost your mood?

Key Points: 
  • So what type of music should you turn to in order to boost your mood?
  • But, as illogical as it may seem, that sensation of sadness may actually help lead to positive emotions.
  • For example, our preference for classical music increases as we age while our preference for rock decreases.
  • But further findings have shown that a listener’s age can also affect the types of music that improve their low mood.

Biotech Industry Veterans Jeff Jonas and Al Robichaud Join Cure Ventures as Partners

Retrieved on: 
Monday, January 8, 2024
Biotechnology, Finance, Health, Professional Services, Asset Management, Ionis Pharmaceuticals, Science, Cure, Drug discovery, Partner, Pramipexole, UC, Juno Therapeutics, Forest Laboratories, DSM-IV codes, Heart, Therapy, Memantine, Growth, Central nervous system, Patient, Organization, Harvard Medical School, Biogen, University of California, Irvine, Pharmaceutical industry

Cure Ventures (“Cure”), a life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, today announced the appointment of industry leaders Jeff Jonas, M.D.

Key Points: 
  • Cure Ventures (“Cure”), a life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, today announced the appointment of industry leaders Jeff Jonas, M.D.
  • and Al Robichaud, Ph.D. as partners to expand the firm’s work with biotech entrepreneurs in developing therapeutics that cure life-altering diseases.
  • It’s clear to me that Cure has the chops to strategically choose its partners and elevate their work.
  • More importantly, he is about as well respected a leader as you can find in our industry,” said Dave Fallace, co-founder and managing partner at Cure Ventures.

Scholar Rock Provides Corporate Update and Highlights Priorities for 2024

Retrieved on: 
Thursday, January 4, 2024
Research, Neurology, Diabetes, Clinical Trials, Cardiology, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Conference, Cure, IND, SAPPHIRE, Spinal muscular atrophy, Clinical trial, Obesity, Standard of care, Annual general meeting, Gongshi, Consequence, Myostatin, DRAGON, Webcast, MPH, Patient, Rock, SMN, SMA, Renal cell carcinoma, SITC, Pharmaceutical industry

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2024.

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2024.
  • Planning to announce Phase 3 SAPPHIRE clinical trial topline data in 4Q 2024.
  • Scholar Rock management will highlight these updates in a corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. PT (4:30 p.m.
  • A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .

Zhihu Announces Receipt of NYSE Notification Regarding ADS Trading Price Requirement

Retrieved on: 
Friday, December 29, 2023
ADS, Cure, Calendar, Letter, Medical device

The NYSE notification does not affect the Company's business operations, its U.S. Securities and Exchange Commission reporting requirements, or contractual obligations.

Key Points: 
  • The NYSE notification does not affect the Company's business operations, its U.S. Securities and Exchange Commission reporting requirements, or contractual obligations.
  • Once notified by the NYSE, the Company must bring its security price and average security price back above US$1.00 by six months (the "Cure Period") following receipt of the notification.
  • In the event that at the expiration of the Cure Period, both a US$1.00 per ADS closing price on the last trading day of the Cure Period and a US$1.00 per ADS average closing price over the 30 trading-day period ending on the last trading day of the Cure Period are not attained, the NYSE will commence suspension and delisting procedures.
  • As required by the NYSE Listed Company Manual, the Company expects to notify the NYSE of its intent to cure its ADS trading price deficiency within the applicable time period required by the NYSE.

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

Retrieved on: 
Tuesday, December 19, 2023
CSF, Patient, Nosebleed, Cure, Risk, Șaeș, Interest, Pulmonary embolism, PIN, Depression, FRCP, Headache, TMS, CHDI, Brain, Neurofilament, SAE, Clinical trial, TFC, Natural history, Event, Inflammation, Hypothermia, AFL, University College London, Biomarker, Back pain, Suicidal ideation, Central nervous system, Frasier, Deep vein thrombosis, UCL, Pharmaceutical industry

The U.S. study consists of a blinded 12-month core study period followed by unblinded long-term follow-up of five years for treated patients.

Key Points: 
  • The U.S. study consists of a blinded 12-month core study period followed by unblinded long-term follow-up of five years for treated patients.
  • Six patients were treated with AMT-130 in the initial low-dose cohort and seven patients were treated in the subsequent high-dose cohort.
  • The cohort includes 31 patients that met the uniQure clinical trial inclusion criteria of Total Functional Capacity, Diagnostic Classification Level and minimum striatal volumes.
  • In mid-2024, uniQure expects to present another clinical update from the ongoing Phase I/II studies of AMT-130, including additional follow-up data from the treated patients in the U.S. and European trials.

New study finds the majority of cancer patients use online resources at least several times a week to manage their care

Retrieved on: 
Tuesday, December 19, 2023
Patient, Roger Hawkins (drummer), Breast cancer, Physician, Data analysis, Estate (law), Cancer, Empowerment, Cure, Face, Overalls, Inc., Pharmaceutical industry

BOSTON, Dec. 19, 2023 /PRNewswire/ -- Outcomes4Me Inc., the developer of the first direct-to-patient, personalized, and evidence-based cancer navigation platform, announced today the results of its second annual State of Patient Empowerment Report. The report is based upon a survey of more than 450 breast cancer patients and data from more than 850 medical records requests across 667 medical centers in every U.S. state. The study uncovered that only half of patients (51%) felt their care team was fully accessible to answer questions during active treatment and only a third of patients were fully satisfied with the information they received from their care team during both active treatment and survivorship.

Key Points: 
  • Patients remain at a disadvantage if they rely solely upon their provider for information to guide their care.
  • Strains on the healthcare system and staffing challenges within the oncology workforce, combined with the fact that the majority of cancer patients receive their care in a community-oncology setting, lead to significant knowledge disparities among cancer patients."
  • Information and access gaps are driving self-advocacy online: 69% of patients use online resources at least several times a week to manage their care, while 34% of patients sought a second opinion from another provider.
  • Additionally, more than half of patients would be willing to share their medical records with an online platform if doing so would help them to manage their cancer care.